Territory Manager THV - Eastern Canada

Edwards Lifesciences has won US Food and Drug Administration (FDA) approval for its PASCAL Precision system to repair tricuspid valves. The system treats patients with symptomatic severe tricuspid regurgitation who remain unwell despite optimal medical therapy and face intermediate or greater surgical risk. The approval makes Edwards the only company in the US offering both repair and replacement transcatheter therapies for the mitral and tricuspid valves. The FDA also approved the PASCAL Ace with Capture Clarity system for mitral repair. It is the first approved device of its kind with fluoroscopic indicators that confirm when valve leaflets have been grasped. One-year data from the CLASP IITR pivotal trial will be presented at Transcatheter Cardiovascular Therapeutics.

Edwards recall exposes post-market surveillance gap in high-risk devices. Sherif Elkhadem 19 October 2026 Edwards Lifesciences is recalling delivery systems for its Sapien M3 transcatheter mitral valve replacement devices after three reports of balloon ruptures during inflation, one of which resulted in patient death. The recall, reported to FDA, affects devices shipped between specific lot ranges, and Edwards is asking customers to return the units immediately. This is not an isolated manufacturing slip. It is evidence that post-market surveillance architecture, even at tier-one manufacturers, often fails to catch field performance gaps before they escalate to serious injury or death. Meanwhile, MHRA's consultation on allowing schools to stock adrenaline nasal sprays signals a different regulatory posture: expanding access to life-saving devices while managing risk through clear use protocols. For device manufacturers, these two stories expose the tension between innovation velocity and the post-market systems required to sustain it. What happened with Edwards' Sapien delivery systems. Edwards received three reports of balloons bursting when inflated during transcatheter mitral valve replacement procedures. The balloon is a critical component of the delivery system, used to expand and position the valve within the patient's heart. When it fails at the point of deployment, the consequences are immediate and severe. One patient died. The others experienced serious complications requiring intervention. Edwards has not yet disclosed the root cause, but the recall notice identifies specific lot numbers, suggesting a batch-related defect rather than a systemic design flaw. This recall follows a well-worn pattern. A high-risk device reaches the market after rigorous pre-market review. Field use reveals a failure mode that was not captured in clinical trials or risk analysis. Injuries accumulate. The manufacturer initiates a recall. Post-market surveillance, in theory, exists to close this loop faster. In practice, the architecture often lags behind the pace of deployment, especially for devices used in complex, high-acuity procedures where failure modes are rare but catastrophic. The Sapien M3 platform is not a newcomer. Edwards has deployed transcatheter valve systems across multiple anatomies and geographies for years. The recall underscores that even mature platforms require continuous monitoring, not just at the device level but across the supply chain, manufacturing process, and post-market feedback loops. For RA and quality teams, this is a reminder that post-market vigilance cannot be episodic. It must be embedded in the operational architecture from day one. MHRA's adrenaline spray consultation offers a contrasting signal. MHRA is consulting on proposals to allow schools in the UK to keep spare adrenaline nasal sprays on site for emergency use in anaphylaxis. The consultation seeks input on the legal framework, storage requirements, training protocols, and liability considerations. Unlike the Edwards recall, this is a proactive regulatory intervention designed to expand access while managing risk through clear use restrictions and oversight mechanisms. The proposal reflects a shift in how regulators think about risk in the field. Rather than restricting access until all edge cases are resolved, MHRA is exploring how to deploy a proven intervention in a controlled, high-need setting with appropriate safeguards. The consultation acknowledges that schools are not clinical environments and that lay users will be the ones administering the device. The regulatory question is not whether the device works, it is whether the use context can be structured to mitigate misuse, delay, or failure to act. For device manufacturers, this signals an opportunity. Regulators are willing to expand the deployment envelope for devices that address unmet needs, provided the post-market architecture is robust. That architecture includes user training, storage protocols, adverse event reporting, and clear communication about when and how the device should be used. It is the inverse of the Edwards recall: proactive risk management rather than reactive damage control. Where post-market surveillance architecture breaks down. The Edwards recall exposes three structural gaps that persist across the industry. First, post-market data flows are too slow. By the time three balloon ruptures were reported, investigated, and escalated to a recall decision, the implicated devices had already been shipped and potentially used. Real-time post-market surveillance systems exist, but they are not yet standard practice, especially for devices distributed through complex hospital supply chains. Second, risk analysis often underestimates low-frequency, high-severity failure modes. Balloon rupture during deployment may be statistically rare, but the clinical consequences are immediate and irreversible. Third, batch variability in manufacturing is still treated as an exception rather than a baseline assumption. If lot-specific defects can evade pre-market quality controls, then post-market monitoring must be granular enough to catch them before they propagate. These gaps are not unique to Edwards. Medtronic's pH capsule recall, tied to 184 serious injuries over two years, revealed similar patterns. So did Johnson & Johnson's Impella pump reports of three deaths. The common thread is not negligence. It is a systemic underinvestment in the post-market architecture required to match the pace of device deployment. Manufacturers that treat post-market surveillance as a compliance burden rather than an operational imperative are playing catch-up after harm has already occurred. What this means for your team. For regulatory affairs and quality teams, the Edwards recall is a test case. If your post-market surveillance system depends on voluntary adverse event reports filtered through distributors, you are flying blind. Real-time feedback loops, batch traceability, and automated signal detection are no longer nice-to-have capabilities. They are the baseline for managing high-risk devices in the field. The MHRA consultation on adrenaline sprays offers a blueprint. Regulators are willing to expand deployment envelopes, but only if the post-market architecture is designed for the use context from the start. That means defining training requirements, storage protocols, and reporting mechanisms before the device ships, not after harm accumulates. MHRA's broader regulatory modernisation strategy, detailed in recent signals on AI integration, supply chain oversight, and enforcement capacity, underscores where regulatory capacity is heading. Post-market surveillance is no longer a passive data collection exercise. It is an active regulatory tool, and manufacturers that build it into their operational architecture will have a competitive advantage in both market access and risk mitigation. The immediate action for RA teams is to audit your post-market surveillance workflows. Can you trace device performance back to lot numbers in real time? Do you have automated triggers for adverse event thresholds? Are you monitoring field use patterns, or just waiting for formal reports to land? If the answer to any of these is no, you are operating with the same blind spots that led to the Edwards recall. The regulatory environment is moving toward continuous oversight. Your post-market systems need to match that pace. Key takeaways. * Edwards' Sapien delivery system recall, tied to one death and three balloon ruptures, exposes post-market surveillance gaps that persist even at tier-one manufacturers. * MHRA's consultation on school-based adrenaline sprays signals regulatory willingness to expand device deployment envelopes, provided post-market architecture is designed for the use context from the start. * The gap between proactive risk management and reactive recall response is a function of post-market surveillance architecture, not manufacturer intent or device complexity. * Real-time batch traceability, automated adverse event triggers, and continuous risk file updates are no longer optional for high-risk devices. They are the operational baseline for matching regulatory oversight expectations. * RA and quality teams should audit post-market workflows now, simulating recall readiness quarterly and integrating field performance data into risk management files as a continuous process, not a periodic compliance exercise. The Edwards recall and MHRA's adrenaline spray consultation are not parallel stories. They are two ends of the same spectrum. One reveals what happens when post-market systems lag behind deployment. The other shows what regulators expect when manufacturers build risk management into the field architecture from the start. For device manufacturers navigating EU MDR, IVDR, MHRA, and FDA oversight, the lesson is clear: post-market surveillance is not the last chapter of the regulatory playbook. It is the operational foundation that determines whether innovation reaches patients safely or becomes a recall statistic.